Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / KURA - Kura Oncology teams up with Novartis for head and neck squamous cell carcinoma study

KURA - Kura Oncology teams up with Novartis for head and neck squamous cell carcinoma study

Kura Oncology Inc.
Kura Oncology (KURA) announces a clinical collaboration with Novartis (NVS) to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma ((HNSCC)) whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification.The Phase 1/2 KURRENT trial is a biomarker-defined cohort study designed to evaluate the safety, determine the recommended combination dosing and assess early anti-tumor activity of the drug combination for the treatment of HNSCC patients.Under the collaboration, Kura maintains global development and commercial rights to tipifarnib.

For further details see:

Kura Oncology teams up with Novartis for head and neck squamous cell carcinoma study
Stock Information
Company Name: Kura Oncology Inc.
Stock Symbol: KURA
Market: NASDAQ
Website: kuraoncology.com
Menu
KURA KURA Quote KURA Short KURA News KURA Articles KURA Message Board
Get KURA Alerts

News, Short Squeeze, Breakout and More Instantly...